Education
About Us
Working with TipRanks
Follow Us
Exagen Inc (XGN)
NASDAQ:XGN
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.15Last Year’s EPS
-0.16Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 05, 2025
|% Change Since: -0.17%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Neutral
The call presents a positive outlook with record revenue growth, successful strategic initiatives, and progress in reimbursement strategies. However, challenges remain with gross margin pressures and increased operating expenses impacting profitability.Company Guidance
During Exagen Inc.'s Q1 2025 earnings call, the company provided guidance indicating a strong start to the year with record revenue of $15.5 million, an 8% increase compared to Q1 2024, and a trailing 12-month average selling price (ASP) of $419 per test, reflecting a $15 increase due to new biomarkers. The company expects full-year revenue of at least $65 million and aims to achieve positive adjusted EBITDA by Q4 2025. Exagen highlighted several strategic initiatives, including winning their first administrative law judge (ALJ) hearing to bolster reimbursement efforts, securing positive medical policy with TRICARE, and anticipating a $90 ASP increase by year-end. Additionally, the company is focused on expanding its test volume, which grew by 6% over Q4 2024, and continuing the development of new seronegative markers expected to launch around the end of the year, potentially increasing sensitivity for rheumatoid arthritis patients by 8%. Exagen also improved its financial position with a new credit facility from Perceptive Advisors, offering access to up to $50 million for future growth, including up to $30 million for strategic transactions.Record Revenue Growth
Exagen Inc. achieved record revenue of $15.5 million, representing an 8% increase compared to the first quarter of the previous year.
New Biomarker Launch
The launch of new biomarkers is driving volume growth, with a 6% increase over the previous quarter and an anticipated $90 increase in ASP by year-end.
Successful ALJ Hearing
Exagen won its first Administrative Law Judge hearing regarding a Medicare Advantage denial, setting a positive precedent for future appeals.
TRICARE Positive Medical Policy
Secured a positive medical policy with TRICARE, enhancing reimbursement and validation of clinical utility.
New Credit Facility
Established a new credit facility with Perceptive Advisors, providing increased borrowing capacity and financial flexibility.
---
XGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
XGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2025 | $6.02 | $6.25 | +3.82% |
Mar 11, 2025 | $2.85 | $3.37 | +18.25% |
Nov 12, 2024 | $2.97 | $2.79 | -6.06% |
Aug 05, 2024 | $2.04 | $2.40 | +17.65% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Exagen Inc (XGN) report earnings?
Exagen Inc (XGN) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is Exagen Inc (XGN) earnings time?
Exagen Inc (XGN) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XGN EPS forecast?
XGN EPS forecast for the fiscal quarter 2025 (Q2) is -0.15.
---